Pharmacological Activity and Clinical Use of PDRN

The document from April 26, 2017, reviews the pharmacological activity and clinical use of Polydeoxyribonucleotide (PDRN), a drug derived from salmon or trout sperm DNA, known for its tissue repairing, anti-ischemic, and anti-inflammatory properties. PDRN works by activating adenosine A2A receptors, aiding DNA synthesis and cell proliferation, and has been effective in improving wound healing and angiogenesis, especially in diabetic conditions. Clinical studies, including one with 110 patients, have shown PDRN to significantly enhance healing in diabetic foot ulcers and other conditions like pressure ulcers, venous ulcers, and degenerative joint disease. It has also been used to treat lichen sclerosus, chronic plantar fasciitis, and female pattern hair loss. PDRN has an excellent safety profile, with no toxic effects or mortality observed in animal studies and good tolerability in human trials. The document emphasizes that PDRN's therapeutic effects are distinct from other DNA-derived drugs and that any new drug claiming bioequivalence should undergo thorough testing for efficacy and safety.